Rexahn Looks For Breakthrough Year With Three Clinical Candidates
• By The Pink Sheet
Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
